The impact of parathyroid hormone supplementation on dental implant osseointegration in osteoporotic subjects: A systematic review.

BACKGROUND

Dental implant osseointegration remains a significant clinical challenge in patients with compromised bone health, particularly in those affected by osteoporosis. Parathyroid hormone (PTH; teriparatide, PTH 1-34) is an established osteoanabolic agent with recognized impacts on bone remodelling. Its use has been proposed as an adjunctive strategy to enhance peri-implant bone regeneration under osteoporotic conditions. This updated systematic review provides evidence from preclinical evaluations of the effects of PTH supplementation on dental implant osseointegration in osteoporotic animal models. We conducted an indexed database search for studies published between January 2015 and August 2025. Outcomes were assessed using histomorphometry, microcomputed tomography, and biomechanical parameters. Methodological quality was assessed using SYRCLE's risk-of-bias tool.

HIGHLIGHTS: • Intermittent PTH administration consistently enhanced peri-implant outcomes in osteoporotic animal models. • Combination regimens outperform PTH monotherapy in osteoporotic models. • Methodological heterogeneity limits clinical translation of preclinical findings.

CONCLUSION

Preclinical evidence supports PTH supplementation as a promising adjunct to enhance peri-implant bone quality and mechanical stability in osteoporotic settings. To date, substantial heterogeneity in experimental design, outcome assessment, and study quality limits meta-analysis and translational interpretation. Standardized outcome measures and robust human trials are required before clinical applications can be considered.